Diclofenac Ophthalmic (Voltaren)

Diclofenac ophthalmic is a non-steroidal anti-inflammatory drug formulated for topical application to the eye, providing effective control of ocular inflammation and pain in horses without the risks associated with corticosteroid therapy. This medication, marketed under the brand name Voltaren among others, represents an important therapeutic option in equine ophthalmology, particularly in situations where corticosteroids are contraindicated or when practitioners seek to minimize steroid exposure. Diclofenac ophthalmic has become an established component of the equine veterinary formulary for managing a variety of inflammatory eye conditions.

The mechanism of action of diclofenac involves inhibition of cyclooxygenase enzymes, thereby blocking the production of prostaglandins that mediate inflammation, pain, and certain pathological processes within the eye. Prostaglandins play significant roles in ocular inflammation, contributing to vasodilation, increased vascular permeability, and activation of pain receptors. By reducing prostaglandin synthesis at the site of application, diclofenac effectively decreases these inflammatory responses. Additionally, diclofenac has been shown to help maintain pupil dilation during intraocular procedures and may help prevent surgically induced miosis, making it valuable in perioperative settings.

Diclofenac ophthalmic is available as a sterile solution designed for direct application to the eye. The typical formulation contains diclofenac sodium at a concentration of 0.1 percent, along with preservatives and buffering agents to maintain stability and comfort upon application. The solution is applied as drops directly into the conjunctival sac, where it absorbs into ocular tissues to exert its anti-inflammatory effects. Dosing frequency varies based on the condition being treated and veterinary recommendations, typically ranging from two to four times daily for most indications.

The safety profile of diclofenac ophthalmic differs significantly from corticosteroid preparations, offering important advantages in specific clinical scenarios. Unlike corticosteroids, topical ophthalmic NSAIDs do not suppress local immune responses to the same degree, making them safer options when infection is a concern. Critically, diclofenac can be used in the presence of corneal ulceration to control inflammation while the ulcer heals, a situation where corticosteroids are absolutely contraindicated. However, diclofenac ophthalmic is not without risks, and veterinary supervision remains essential. Some evidence suggests that topical NSAIDs may delay corneal epithelial healing, and rare but serious complications including corneal melting have been reported, particularly with prolonged use or in compromised corneas.

One of the most valuable applications of diclofenac ophthalmic in equine practice is the management of inflammation associated with corneal ulceration. Corneal ulcers represent common and potentially vision-threatening emergencies in horses, often resulting from trauma, foreign bodies, or infection. While the ulcer itself requires appropriate antimicrobial therapy and supportive care, the accompanying inflammation causes pain and can contribute to pathological processes that impair healing or cause additional damage. Diclofenac provides anti-inflammatory and analgesic effects without the immune suppression and healing inhibition associated with corticosteroids, making it the preferred anti-inflammatory option when corneal epithelial defects are present.

Post-surgical inflammation management represents another primary indication for diclofenac ophthalmic in horses. Following procedures such as eyelid surgery, conjunctival grafting, corneal surgery, or intraocular procedures, controlled inflammation supports optimal healing outcomes. Diclofenac effectively reduces postoperative inflammation and discomfort while potentially minimizing complications such as excessive scarring or adhesion formation. The medication may be used alone or in combination with corticosteroids depending on the procedure performed and the veterinarian's assessment of infection risk and healing requirements.

Diclofenac ophthalmic serves as an adjunct or alternative therapy for equine recurrent uveitis and other forms of anterior uveitis in horses. While corticosteroids remain the mainstay of uveitis treatment due to their potent anti-inflammatory effects, situations exist where reducing corticosteroid exposure is desirable. Diclofenac may be used alongside reduced corticosteroid doses, during the tapering phase of corticosteroid therapy, or as maintenance therapy between acute flares. The prostaglandin-mediated miosis associated with uveitis may respond particularly well to NSAID therapy, helping maintain more normal pupil function.

Prevention of intraoperative miosis represents a specific indication where diclofenac ophthalmic provides significant clinical benefit. During intraocular procedures, maintaining pupil dilation is essential for surgical visualization and access. Prostaglandins released during surgical manipulation cause pupil constriction that can complicate procedures. Pre-treatment with diclofenac ophthalmic in the hours or days preceding surgery helps prevent this surgically induced miosis, improving conditions for the surgeon and potentially improving outcomes.

Allergic and irritant conjunctivitis may also respond to diclofenac ophthalmic therapy, particularly in cases where corticosteroid use is to be minimized or avoided. While the anti-inflammatory potency of topical NSAIDs is generally less than that of corticosteroids, mild to moderate conjunctival inflammation often responds adequately to NSAID therapy. This approach may be particularly appropriate for horses with recurrent seasonal allergies where long-term treatment is anticipated. The favorable safety profile regarding infection risk makes diclofenac a reasonable option for managing inflammatory conditions in horses with concurrent ocular surface disease.

The dosing protocol for diclofenac ophthalmic in horses is established by the treating veterinarian based on the specific clinical situation, condition severity, and treatment goals. Unlike systemic medications where body weight directly determines dose, ophthalmic medications are dosed by frequency and number of drops per application. The standard concentration of diclofenac ophthalmic solution is 0.1 percent, and this single concentration is used across all indications with variation in application frequency rather than drug strength. Horse owners should follow the prescribed regimen precisely and not adjust frequency without veterinary consultation.

For managing inflammation associated with corneal ulcers, diclofenac ophthalmic is typically prescribed two to four times daily, with frequency determined by the severity of inflammation and pain observed. Treatment continues alongside appropriate antimicrobial therapy and other supportive care until the ulcer has healed and inflammation has resolved. The veterinarian monitors healing progress through regular examinations including fluorescein staining and adjusts the treatment protocol as needed. More frequent dosing may be indicated initially for severe inflammation, with reduction as clinical improvement occurs.

Post-surgical protocols often involve pre-operative administration beginning one to several days before the procedure, followed by continued treatment for days to weeks afterward depending on the surgery performed. For preventing intraoperative miosis specifically, treatment typically begins twenty-four to forty-eight hours before surgery with applications every four to six hours to adequately suppress prostaglandin production. Post-operative treatment continues at the veterinarian's direction based on observed inflammation and healing response.

For uveitis management and other inflammatory conditions, diclofenac ophthalmic dosing varies considerably based on whether it is used as primary therapy, adjunct therapy, or maintenance therapy. When used alongside corticosteroids during acute flares, both medications follow their prescribed schedules with appropriate spacing between applications. As a maintenance or corticosteroid-sparing option, twice to four times daily application is common. Long-term use requires periodic veterinary assessment to evaluate continued need and monitor for adverse effects.

Proper administration technique ensures adequate drug delivery and minimizes complications. The handler should approach the horse calmly and clean any discharge from around the eye before application. The lower eyelid is gently retracted to expose the conjunctival sac, and one to two drops are applied directly into this pocket, depending on the veterinarian's instructions. The dropper tip must not contact the eye or surrounding tissues to maintain sterility. After application, the horse may blink or exhibit mild transient discomfort, which is normal. When multiple eye medications are prescribed, a minimum of five minutes should separate applications of different preparations.

Missed doses should be administered when remembered unless the next scheduled dose is approaching, in which case the missed dose is skipped. Doubling doses to compensate for missed applications is not recommended and increases the risk of adverse effects. If multiple consecutive doses are missed, contacting the veterinarian for guidance on resuming treatment is advisable. Consistent, regular administration optimizes therapeutic outcomes, and establishing a routine helps ensure compliance.

Diclofenac ophthalmic is generally well tolerated by horses when used as directed under veterinary supervision. The most commonly observed effects are mild and localized, representing normal tissue responses to the medication rather than adverse reactions requiring intervention. However, awareness of potential side effects enables early recognition of complications and prompt veterinary attention when needed, supporting the best possible outcomes for treated horses.

Mild transient discomfort upon application is the most frequently observed effect of diclofenac ophthalmic in horses. This may manifest as brief stinging or burning sensation, increased blinking, mild tearing, or head movement following drop instillation. These responses typically resolve within one to two minutes and do not indicate intolerance to the medication or need for discontinuation. The discomfort relates to normal sensory responses to foreign substances in the eye and to the slightly acidic or basic pH of the medication compared to natural tears.

Corneal effects represent the most significant potential adverse effects of topical ophthalmic NSAIDs including diclofenac. While one advantage of NSAIDs over corticosteroids is the ability to use them in the presence of corneal ulcers, evidence suggests that diclofenac and related drugs may slow corneal epithelial healing to some degree. This effect is generally mild and clinically acceptable when weighed against the benefits of inflammation control, but veterinarians consider this factor when designing treatment protocols for ulcerative keratitis. Close monitoring of healing progress during treatment is essential.

Rare but serious complications including corneal melting or thinning have been reported with topical ophthalmic NSAID use, particularly with prolonged treatment or in compromised corneas. These complications appear to result from effects on corneal stromal integrity and may be related to matrix metalloproteinase activity. While such complications are uncommon, they underscore the importance of veterinary supervision and regular monitoring during treatment. Any worsening of corneal appearance, increased pain, or changes suggesting complications requires immediate veterinary evaluation and likely discontinuation of the medication.

Systemic side effects from topical ophthalmic diclofenac are minimal due to the limited absorption from ocular administration. The small amount of drug that enters systemic circulation through nasolacrimal drainage and conjunctival absorption is generally insufficient to cause the gastrointestinal, renal, or other effects associated with systemic NSAID administration in horses. However, horses receiving systemic NSAIDs concurrently may experience additive effects, and veterinarians consider total NSAID exposure from all sources when prescribing treatments. Any signs suggesting systemic effects should be reported to the veterinarian.

Known hypersensitivity to diclofenac, other NSAIDs, or any component of the ophthalmic formulation represents an absolute contraindication to use. Horses with documented allergic reactions to diclofenac or related medications should not receive this product. Cross-sensitivity between different NSAIDs may occur, so horses with known adverse reactions to any NSAID should be treated with caution if an alternative ophthalmic NSAID is considered. Signs of hypersensitivity may include worsening inflammation, severe irritation, or other unexpected adverse responses that do not improve with continued treatment.

While diclofenac ophthalmic can be used in the presence of corneal ulceration, which represents an advantage over corticosteroids, certain complicated corneal conditions warrant caution or avoidance. Deep stromal ulcers, descemetoceles, or corneas showing signs of progressive melting may be at increased risk for complications with any anti-inflammatory therapy. The decision to use diclofenac in complicated corneal disease requires careful veterinary assessment of risks and benefits for each individual case. If corneal integrity is severely compromised, the priority shifts entirely to surgical intervention and antimicrobial therapy.

Horses with bleeding disorders or those receiving anticoagulant therapy require careful consideration before using diclofenac ophthalmic. NSAIDs inhibit platelet function through cyclooxygenase inhibition, potentially increasing bleeding tendency. While systemic effects from topical ophthalmic administration are minimal, horses with significant coagulopathies or those on systemic anticoagulant medications should be monitored carefully. Any unusual bleeding or bruising around the eye during treatment should be reported to the veterinarian.

Concurrent use of multiple ophthalmic NSAID preparations is generally contraindicated due to the lack of additional benefit and potential for increased adverse effects. Similarly, while combining topical NSAIDs with topical corticosteroids may be indicated in specific situations, this approach requires veterinary supervision to ensure appropriate use and monitoring. Horses with a history of adverse reactions to ophthalmic medications should have new treatments introduced cautiously with close monitoring for unexpected responses. Pregnant mares represent a population where caution is warranted due to the known effects of systemic NSAIDs on pregnancy, though systemic absorption from ophthalmic administration is limited.

When multiple ophthalmic medications are prescribed concurrently, proper spacing between applications is essential to ensure adequate absorption and effect of each agent. Diclofenac ophthalmic should be administered at least five to ten minutes apart from other eye drops or ointments. This interval allows sufficient time for the first medication to absorb into ocular tissues before the next is applied. When both solutions and ointments are prescribed, solutions should generally be administered first, as ointments create a barrier that impairs absorption of subsequently applied medications.

The combination of topical ophthalmic NSAIDs with topical corticosteroids is sometimes employed therapeutically to achieve enhanced anti-inflammatory effects or to allow reduced corticosteroid dosing. However, this combination requires veterinary supervision and appropriate monitoring. Both drug classes affect inflammatory pathways, and while their mechanisms differ, concurrent use increases the overall anti-inflammatory burden on ocular tissues. The combination may be particularly useful during transitions from high-dose corticosteroid therapy or in managing severe inflammation while minimizing individual drug exposure.

Systemic NSAID administration concurrent with topical ophthalmic diclofenac represents a consideration for total NSAID exposure. While absorption from ophthalmic administration is minimal, horses receiving systemic phenylbutazone, flunixin meglumine, firocoxib, or other NSAIDs are already experiencing cyclooxygenase inhibition throughout the body. The additional ocular NSAID is unlikely to significantly increase systemic effects but represents additional drug exposure that veterinarians consider when designing comprehensive treatment plans. The critical systemic NSAID stacking warnings regarding never combining multiple systemic NSAIDs remain paramount, while topical ophthalmic NSAIDs present minimal systemic interaction risk.

Topical ophthalmic antibiotics and antifungals are frequently prescribed alongside diclofenac when treating infected or potentially infected corneal conditions. These combinations are therapeutically appropriate with proper administration spacing. Some evidence suggests that NSAIDs may have mild antimicrobial properties themselves, though this is not relied upon therapeutically. Competition horses receiving diclofenac ophthalmic should be aware that this medication, like all NSAIDs, is subject to competition regulations. While detection from topical ophthalmic administration may be limited, consultation with veterinarians familiar with competition rules and potentially pre-competition testing is advisable for horses in active competition.

Regular veterinary monitoring during diclofenac ophthalmic treatment ensures appropriate therapeutic response and early identification of any complications. The frequency of examinations depends on the condition being treated and its severity. Corneal ulcers typically require frequent rechecks, often daily or every other day initially, to monitor healing progress and adjust treatment as needed. Less acute conditions may be monitored weekly or as determined by the veterinarian. Examinations include assessment of inflammation, evaluation of corneal integrity, and overall eye health evaluation. Owners should report any changes between scheduled visits.

Special populations of horses require additional consideration when prescribing diclofenac ophthalmic. Foals may have different drug responses compared to adult horses, and treatment protocols should be adjusted accordingly under veterinary guidance. Geriatric horses often have concurrent health conditions that may influence overall treatment planning. Pregnant mares warrant caution with any NSAID due to known effects on fetal development and parturition, though systemic absorption from ophthalmic administration is limited. Horses with known sensitivity to NSAIDs of any type should be treated with particular caution and close monitoring.

Competition horses face regulatory considerations with diclofenac ophthalmic use. The Federation Equestre Internationale, United States Equestrian Federation, and various racing commissions regulate NSAID use in competition horses. While topical ophthalmic administration results in minimal systemic absorption compared to oral or injectable routes, diclofenac may be detectable in samples from treated horses. Detection times depend on formulation, frequency, and duration of treatment. Horse owners and trainers must consider competition schedules when planning treatment, and veterinary consultation regarding appropriate withdrawal times is essential. Current rules should always be verified as regulations change.

Administration precautions protect both handler and horse during medication application. The dropper tip should never contact the eye, eyelids, or surrounding tissues to maintain sterility and prevent injury. Proper restraint ensures accurate placement while keeping handlers safe from sudden head movements. Some horses require gradual desensitization to accept ophthalmic medication, and patience during initial treatments pays dividends in improved compliance throughout the treatment course. Washing hands before and after administration maintains hygiene.

Long-term use of diclofenac ophthalmic requires periodic reassessment of treatment necessity and monitoring for cumulative effects. While topical NSAIDs are generally safer for extended use than corticosteroids, chronic administration still warrants veterinary oversight. Potential corneal effects from prolonged NSAID exposure should be monitored through regular examinations. The lowest effective frequency should be used for maintenance therapy when long-term treatment is necessary. Alternative approaches including immunomodulatory therapies may be considered for chronic conditions to reduce total anti-inflammatory drug exposure over time.

Diclofenac ophthalmic solution should be stored at controlled room temperature between fifteen and twenty-five degrees Celsius (fifty-nine to seventy-seven degrees Fahrenheit), protected from light and excessive heat. The medication should not be frozen, as this can damage the formulation and render it ineffective or potentially harmful. Barn and stable environments often present storage challenges due to temperature fluctuations, so medications may need to be stored in a climate-controlled location and transported to the barn for each administration. The bottle should be kept tightly closed when not in use to prevent contamination and evaporation.

Handling practices for diclofenac ophthalmic focus on maintaining sterility and preventing contamination. The dropper tip should never contact any surface including the eye, eyelids, fingers, or other objects, as this can introduce bacteria or other contaminants into the bottle. Before administration, hands should be washed thoroughly, and the area around the horse's eye should be cleaned of any discharge or debris. The cap should be replaced immediately after dispensing the required drops to minimize exposure to environmental contaminants. If the solution appears cloudy, discolored, or contains particles, it should not be used and the veterinarian should be consulted.

Expiration dates on diclofenac ophthalmic must be strictly observed, as degraded medication may be ineffective or potentially harmful. Additionally, most ophthalmic solutions have recommended discard times after opening that may be shorter than the printed expiration date, typically twenty-eight days for multi-dose containers. Writing the date opened on the bottle helps track this timeline. Expired or outdated medications should be disposed of properly rather than saved for potential future use. While diclofenac does not present significant environmental hazards, proper disposal through pharmacy take-back programs or as directed by local guidelines is preferable to drain disposal. Keeping medications out of reach of children and animals prevents accidental exposure.

Appaloosa horses have significantly increased prevalence of equine recurrent uveitis, making them frequent candidates for anti-inflammatory ophthalmic therapy including diclofenac. While corticosteroids remain primary therapy for acute uveitis episodes, diclofenac may serve as adjunct therapy or for maintenance between flares. Appaloosa owners should be particularly vigilant for signs of uveitis including eye pain, cloudiness, tearing, and squinting, seeking prompt veterinary evaluation. The chronic nature of this condition in many Appaloosas means long-term management strategies, potentially including periodic diclofenac use, become important considerations.

Draft horses including Belgians, Percherons, Clydesdales, and Shires present practical considerations for ophthalmic medication administration. Their larger head and eye size may accommodate medication application more easily in some respects, though handler height may complicate reaching the eye. The generally calm temperament of many draft breeds can facilitate consistent medication administration. Draft horses appear to have similar drug responses to light horse breeds for topical ophthalmic medications, with no specific dose adjustments required based on body size since ophthalmic medications are dosed by application frequency rather than total drug amount.

Ponies and miniature horses require careful, precise application of ophthalmic medications due to their smaller eye size. The closer proximity of ocular structures in smaller equines means accurate medication placement is important for optimal drug delivery. Miniature horses may have proportionally larger eyes relative to head size, which can actually facilitate administration. These smaller equines may be more reactive to handling around the head, requiring patience and proper restraint techniques. Establishing consistent administration routines helps improve acceptance and compliance in all sizes of equines.

Warmbloods, Thoroughbreds, Arabians, and other breeds do not have documented breed-specific responses to diclofenac ophthalmic that require special consideration. Standard dosing protocols apply across breeds, with individual variation in response being more significant than breed factors. However, breed predispositions to certain ocular conditions may influence treatment frequency and duration. For example, breeds with higher uveitis prevalence may require more extended or recurrent courses of anti-inflammatory therapy. Competition horses of any breed must consider withdrawal time requirements relevant to their specific discipline when using diclofenac ophthalmic.

Within the topical ophthalmic NSAID class, several alternatives to diclofenac offer similar therapeutic effects through the same mechanism of cyclooxygenase inhibition. Flurbiprofen ophthalmic (Ocufen) represents a commonly used alternative with similar indications including prevention of intraoperative miosis and management of postoperative inflammation. Ketorolac ophthalmic (Acular) is another option with well-established efficacy for ocular inflammation and pain. These medications share the general benefits and risks of the NSAID class, including the ability to use them in the presence of corneal ulceration and the potential for effects on corneal epithelial healing with prolonged use.

Corticosteroid ophthalmic preparations offer more potent anti-inflammatory effects than NSAIDs and remain the primary choice for many inflammatory eye conditions in horses. Dexamethasone ophthalmic and prednisolone acetate ophthalmic are commonly used corticosteroid options providing powerful suppression of ocular inflammation. However, corticosteroids carry significant risks including immunosuppression that can allow infections to flourish, contraindication in the presence of corneal ulceration, and potential for elevated intraocular pressure with prolonged use. The choice between NSAIDs and corticosteroids depends on the specific clinical situation, presence of corneal defects, and risk-benefit analysis for each patient.

For chronic immune-mediated conditions such as equine recurrent uveitis, cyclosporine ophthalmic preparations offer an immunomodulatory approach distinct from both NSAIDs and corticosteroids. Cyclosporine works by inhibiting T-cell activation and may be effective for long-term management while reducing exposure to traditional anti-inflammatory drugs. This medication may be used alongside diclofenac or corticosteroids in comprehensive treatment protocols. The decision to use cyclosporine typically comes after evaluation of response to initial therapy and consideration of long-term management needs. All medication selections and adjustments should be made by the treating veterinarian based on thorough examination and appropriate monitoring.